SCHEMBL5335920

SCHEMBL5335920

CN(C)C(=O)Nc1ccccc1N1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 5/20 0.49
NAMPT P43490 1/20 0.49
SMARCA2 P51531 1/20 0.47
SMARCA4 P51532 1/20 0.47
PBRM1 Q86U86 1/20 0.47
TSHR P16473 4/20 0.47
MAPT P10636 3/20 0.47
GLA P06280 2/20 0.47
USP2 O75604 1/20 0.47
PTPN11 Q06124 1/20 0.47
ALDH1A1 P00352 4/20 0.46
NPSR1 Q6W5P4 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GPR119 Q8TDV5 1/20 0.45
CKS1B P61024 1/20 0.45
SKP1 P63208 1/20 0.45
SKP2 Q13309 1/20 0.45
MAPK8 P45983 1/20 0.45
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17491558 0.86 NAMPT (0.52) BACE1NAMPTSMARCA2SMARCA4PBRM1
SCHEMBL25634800 0.84 BACE1 (0.49) BACE1NAMPTSMARCA2SMARCA4PBRM1
SCHEMBL5337500 0.83 ALDH1A1 (0.67) BACE1NAMPTTSHRGLAUSP2
SCHEMBL14387753 0.81 BACE1 (0.46) BACE1NAMPTSMARCA2SMARCA4PBRM1
SCHEMBL8133454 0.81 NPSR1 (0.54) TSHRMAPTGLAALDH1A1NPSR1
SCHEMBL5336322 0.81 ALDH1A1 (0.52) BACE1NAMPTSMARCA2SMARCA4PBRM1
SCHEMBL6942726 0.81 ALDH1A1 (0.49) BACE1NAMPTSMARCA2SMARCA4PBRM1
SCHEMBL14355836 0.80 MAPK1 (0.60) TSHRMAPTUSP2ALDH1A1NPSR1
SCHEMBL5335893 0.80 MEN1 (0.69) TSHRMAPTGLAALDH1A1NPSR1
SCHEMBL8985828 0.80 ACHE (0.50) BACE1NAMPTSMARCA2SMARCA4PBRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
US-7291619-B2 Melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-11-06 US disclosed
EP-1368340-B1 PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS LILLY CO ELI (US) 2005-08-10 EP disclosed
US-20040092507-A1 Melanocortin receptor agonists ELI LILLY AND COMPANY 2004-05-13 US disclosed
EP-1368340-A1 PIPERAZINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2003-12-10 EP disclosed
WO-2002059108-A1 MELANOCORTIN RECEPTOR AGONISTS ELI LILLY AND COMPANY (US) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092507-A1 Melanocortin receptor agonists MC1R, MC4R, MC5R BACE1 4081/4885NAMPT 801/4885SMARCA2 4437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.